Two rotavirus vaccines—RotaTeq (RV5; Merck and Company), a 3-dose series, and Rotarix (RV1; GlaxoSmithKline Biologicals), a 2-dose series—are licensed for use in US children. The US Advisory Committee for Immunization Practices (ACIP) recommends that a rotavirus vaccine series be completed with the same product whenever possible but allows for administering mixed vaccine types if a previous dose type is not available or is unknown.1 In such situations, the ACIP recommends, “If any dose in the series was RV5 or the vaccine product is unknown for any dose in the series, a total of 3 doses of rotavirus vaccine should be administered.”1 However, the effectiveness of a mixed rotavirus vaccine series remains unclear.
Payne DC, Sulemana I, Parashar UD, for the New Vaccine Surveillance Network. Evaluation of Effectiveness of Mixed Rotavirus Vaccine Course for Rotavirus Gastroenteritis. JAMA Pediatr. 2016;170(7):708-710. doi:10.1001/jamapediatrics.2016.0014